Pharmacological applications of antioxidants: Lights and shadows

Current Drug Targets

Volumn 15, Issue 13, 2014, Pages 1177-1199

  Saso, Luciano ^a   Firuzi, Omidreza ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antioxidants; Mitochondrial dysfunction; Neurodegenerative diseases; NOX; Nrf2; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIOXIDANT; APOCYNIN; CAFFEIC ACID PHENETYL ESTER; CELASTROL; CURCUMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EBSELEN; ERDOSTEINE; FLAVONOID; FUDOSTEINE; GINKGO BILOBA EXTRACT; MELATONIN; NIMESULIDE; NITROXIDE DERIVATIVE; POLYPHENOL DERIVATIVE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RESVERATROL; SILYMARIN; SIRTUIN; SULFORAPHANE; THIOCTIC ACID; TRANSCRIPTION FACTOR NRF1; TRIAZOLOPYRIMIDINE; TRITERPENOID; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ALOPECIA; ANTIOXIDANT ACTIVITY; ARTICLE; CHELATION; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DERMATITIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG UPTAKE; EPISTAXIS; GENE THERAPY; HUMAN; META ANALYSIS (TOPIC); NERVOUS SYSTEM FUNCTION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PLEIOTROPY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); ANIMAL; CLASSIFICATION; DISEASES; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM;

ANIMALS; ANTIOXIDANTS; DISEASE; GENE EXPRESSION REGULATION; HUMANS; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84923996036     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141024113925     Document Type: Article

References (351)

1. [1] Bonda DJ, Wang X, Perry G, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology 2010; 59: 290-4.
2. [2] Surendran S, Rajasankar S. Parkinson’s disease: oxidative stress and therapeutic approaches. Neurol Sci 2010; 31: 531-40.
3. [3] Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006; 8: 2061-73.
4. [4] Mhatre M, Floyd RA, Hensley K. Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. J Alz Dis 2004; 6: 147-57.
5. [5] Gilgun-Sherki Y, Melamed E. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004; 251: 261-8.
6. [6] Sosa V, Moliné T, Somoza R, et al. Oxidative stress and cancer: an overview. Ageing Res Rev 2012; 12: 376-90.
7. [7] Arreguin F, Garcia N, Hernandez-Resendiz S, et al. Attenuation of oxidant damage in the postconditioned heart involves nonenzymatic response and partial catalytic protection. Exp Physiol 2012; 97: 1119-30.
8. [8] Allen C, Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009; 4: 461-70.
9. [9] Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation—from bench to bedside. Nat Rev Gastroenterol Hepatol 2012.
10. [10] Firuzi O, Fuksa L, Spadaro C, et al. Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 2006; 58: 951-7.
11. [11] Riccieri V, Spadaro A, Fuksa L, et al. Specific oxidative stress parameters differently correlate with nailfold capillaroscopy changes and organ involvement in systemic sclerosis. Clin Rheumatol 2008; 27: 225-30.
12. [12] Firuzi O, Spadaro A, Spadaro C, et al. Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients. J Clin Lab Anal 2008; 22: 210-5.
13. [13] Chiurchiù V, Maccarrone M. Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2011; 15: 2605-41.
14. [14] Lee R, Margaritis M, Channon K, Antoniades C. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. Curr Med Chem 2012; 19: 2504.
15. [15] Peluso I, Morabito G, Urban L, Ioannone F, Serafi M. Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endocr Metab Immune Disord Drug Targets 2012; 12: 351-60.
16. [16] Montezano AC, Touyz RM. Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med 2012; 44: S2-S16.
17. [17] Ahmed Z, Tang WW. Pharmacologic strategies to target oxidative stress in heart failure. Curr Heart Fail Rep 2012; 9: 14-22.
18. [18] Stadler K. Oxidative stress in diabetes. Adv Exp Med Biol 2012; 771: 272-87.
19. [19] Styskal J, Van Remmen H, Richardson A, Salmon AB. Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic Biol Med 2012; 52: 46-58.
20. [20] Miri R, Saadati H, Ardi P, Firuzi O. Alterations in oxidative stress biomarkers associated with mild hyperlipidemia and smoking. Food Chem Toxicol 2012; 50: 920-6.
21. [21] Kaefer M, De Carvalho JA, Piva SJ, et al. Plasma malondialdehyde levels and risk factors for the development of chronic complications in type 2 diabetic patients on insulin therapy. Clin Lab 2012; 58: 973-8.
22. [22] Yao H, Rahman I. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol 2011; 254: 72-85.
23. [23] Dozor AJ. The role of oxidative stress in the pathogenesis and treatment of asthma. Ann NY Acad Sci 2010; 1203: 133-7.
24. [24] Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, antioxidant therapies and chronic kidney disease. Nephrology 2012; 17: 311-21.
25. [25] Maes M, Fiar Z, Medina M, et al. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012; 20: 127-50.
26. [26] Steckert AV, Valvassori SS, Moretti M, Dal-Pizzol F, Quevedo J. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res 2010; 35: 1295-301.
27. [27] Bitanihirwe BK, Woo T-UW. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011; 35: 878-93.
28. [28] Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 1991; 91: S14-S22.
29. [29] Martínez MC, Andriantsitohaina R. Reactive nitrogen species: molecular mechanisms and potential significance in health and disease. Antioxid Redox Signal 2009; 11: 669-702.
30. [30] Roe ND, Ren J. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vasc Pharmacol 2012; 57: 168-72.
31. [31] Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 413-20.
32. [32] Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011; 10: 453-71.
33. [33] Andriantsitohaina R, Duluc L, Garcia-Rodriguez JC, et al. Systems biology of antioxidants. Clin Sci 2012; 123: 173-92.
34. [34] Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab 2012; 302: E481-E495.
35. [35] Tripathi P, Chandra M, Misra MK. Oral administration of Larginine in patients with angina or following myocardial infarction may be protective by increasing plasma superoxide dismutase and total thiols with reduction in serum cholesterol and xanthine oxidase. Oxid Med Cell Longev 2009; 2: 231-7.
36. [36] Okazaki T, Otani H, Shimazu T, et al. Reversal of inducible nitric oxide synthase uncoupling unmasks tolerance to ischemia/reperfusion injury in the diabetic rat heart. J Mol Cell Cardiol 2011; 50: 534-44.
37. [37] Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem 2011; 18: 3871-88.
38. [38] Willcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol 2008; 101: S75-S86.
39. [39] Calabrese V, Cornelius C, Trovato-Salinaro A, et al. The hormetic role of dietary antioxidants in free radical-related diseases. Curr Pharm Design 2010; 16: 877-83.
40. [40] Gillette Guyonnet S, Secher M, Vellas B. Nutrition and neurodegeneration: epidemiological evidence and challenges for future research. Br J Clin Pharmacol 2013; 75: 738-55.
41. [41] Del Rio D, Rodriguez-Mateos A, Spencer JP, et al. Dietary (poly) phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal 2013; 18: 1818-92.
42. [42] Rice-Evans CA, Miller NJ. Antioxidant activities of flavonoids as bioactive components of food. Biochem Soc Trans 1996; 24: 790-95.
43. [43] Aldini G, Vistoli G, Regazzoni L, et al. Edaravone inhibits protein carbonylation by a direct carbonyl-scavenging mechanism: focus on reactivity, selectivity, and reaction mechanisms. Antioxid Redox Sinal 2010; 12: 381-92.
44. [44] Aruoma OI, Smith C, Cecchini R, Evans PJ, Halliwell B. Free radical scavenging and inhibition of lipid peroxidation by betablockers and by agents that interfere with calcium metabolism. A physiologically-significant process? Biochem Pharmacol 1991; 42: 735-43.
45. [45] Doeppner TR, Hermann DM. Free radical scavengers and spin traps-therapeutic implications for ischemic stroke. Best Pract Res Clin Anaesthesiol 2010; 24: 511-20.
46. [46] Firuzi O, Giansanti L, Vento R, et al. Hypochlorite scavenging activity of hydroxycinnamic acids evaluated by a rapid microplate method based on the measurement of chloramines. J Pharm Pharmacol 2003; 55: 1021-7.
47. [47] Moorhouse PC, Grootveld M, Halliwell B, Quinlan JG, Gutteridge J. Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS lett 1987; 213: 23-8.
48. [48] Yoshida H, Yanai H, Namiki Y, et al. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 2006; 12: 9-20.
49. [49] Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593-7.
50. [50] Bubols GB, Vianna Dda R, Medina-Remon A, et al. The antioxidant activity of coumarins and flavonoids. Mini Rev Med Chem 2013; 13: 318-34.
51. [51] Mladenka P, Macakova K, Filipsky T, et al. In vitro analysis of iron chelating activity of flavonoids. J Inorg Biochem 2011; 105: 693-701.
52. [52] Zheng H, Amit T, Bar-Am O, et al. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. J Alz Dis 2012; 30: 1-16.
53. [53] Trujillo J, Chirino YI, Molina-Jijon E, et al. Renoprotective effect of the antioxidant curcumin: Recent findings. Redox Biol 2013; 1: 448-56.
54. [54] Gonzalez-Burgos E, Gomez-Serranillos MP. Terpene compounds in nature: a review of their potential antioxidant activity. Curr Med Chem 2012; 19: 5319-41.
55. [55] Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. The role of melatonin in acute myocardial infarction. Front Biosci 2012; 17: 2433-41.
56. [56] Stahl W, Sies H. beta-Carotene and other carotenoids in protection from sunlight. Am J Clin Nutr 2012; 96: 1179-84.
57. [57] Lu MF, Xiao ZT, Zhang HY. Where do health benefits of flavonoids come from? Insights from flavonoid targets and their evolutionary history. Biochem Biophys Res Commun 2013; 434: 701-4.
58. [58] Hollman PC, Cassidy A, Comte B, et al. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. J Nutr 2011; 141: 989-1009.
59. [59] Sies H. Polyphenols and health: update and perspectives. Arch Biochem Biophys 2010; 501: 2-5.
60. [60] Vauzour D. Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. Oxid Med Cell Longev 2012; 2012: 914273.
61. [61] Mladnka P, Zatloukalová L, Filipsk T, Hrdina R. Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Radic Biol Med 2010; 49: 963-75.
62. [62] Hu M-L. Dietary polyphenols as antioxidants and anticancer agents: more questions than answers. Chang Gung Med J 2011; 34: 449-60.
63. [63] Halliwell B, Rafter J, Jenner A. Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? Am J Clin Nutr 2005; 81: 268S-76S.
64. [64] Terao J. Dietary flavonoids as antioxidants. Forum Nutr 2009; 61: 87-94.
65. [65] Fraccarollo D, Widder JD, Galuppo P, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008; 118: 818-27.
66. [66] Frantz S, Adamek A, Fraccarollo D, et al. The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. Basic Res Cardiol 2009; 104: 773-79.
67. [67] Margaritis M, Channon KM, Antoniades C. Statins as Regulators of Redox State in the Vascular Endothelium: Beyond Lipid Lowering. Antioxid Redox Signal 2014; 20(8): 1198-215.
68. [68] Ghosh N, Ghosh R, Mandal SC. Antioxidant protection: a promising therapeutic intervention in neurodegenerative disease. Free Rad Res 2011; 45: 888-905.
69. [69] Hall ED. Antioxidant therapies for acute spinal cord injury. Neurotherapeutics 2011; 8: 152-67.
70. [70] Lönn ME, Dennis JM, Stocker R. Actions of “antioxidants” in the protection against atherosclerosis. Free Radic Biol Med 2012; 53: 863-84.
71. [71] Wu BJ, Kathir K, Witting PK, et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med 2006; 203: 1117-27.
72. [72] Chan KH, Ng MK, Stocker R. Haem oxygenase-1 and cardiovascular disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2011; 120: 493-504.
73. [73] Tinkel J, Hassanain H, Khouri SJ. Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms. Cardiol Rev 2012; 20: 77-83.
74. [74] Joshi G, Johnson JA. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov 2012; 7: 218-29.
75. [75] Cai L. Preventive and Therapeutic Effects of MG132 by Activating Nrf2-ARE Signaling Pathway on Oxidative Stress-Induced Cardiovascular and Renal Injury. Oxid Med Cell Longev 2013; 2013
76. [76] Magesh S, Chen Y, Hu L. Small Molecule Modulators of Keap1Nrf2ARE Pathway as Potential Preventive and Therapeutic Agents. Med Res Rev 2012; 32: 687-726.
77. [77] Zhao J, Moore AN, Redell JB, Dash PK. Enhancing expression of Nrf2-driven genes protects the blood-brain barrier after brain injury. J Neurosci 2007; 27: 10240-8.
78. [78] Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Ann Rev Physiol 2009; 71: 451-64.
79. [79] Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta 2012; 1822: 714-28.
80. [80] Boutten A, Goven D, Artaud-Macari E, Boczkowski J, Bonay M. NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease. Trends Mol Med 2011; 17: 363-71.
81. [81] Tapia E, Soto V, Ortiz-Vega KM, et al. Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats. Oxid Med Cell Longev 2012; 2012: 269039.
82. [82] Holtzclaw WD, Dinkova-Kostova AT, Talalay P. Protection against electrophile and oxidative stress by induction of phase 2 genes: the quest for the elusive sensor that responds to inducers. Adv Enz Reg 2004; 44: 335-67.
83. [83] Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. Biochem Pharmacol 2013; 85: 705-17.
84. [84] Zhang M, An C, Gao Y, et al. Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol 2013; 100: 30-47.
85. [85] Luo M, He H, Kelley MR, Georgiadis MM. Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid Redox Signal 2010; 12: 1247-69.
86. [86] Barbagallo I, Galvano F, Frigiola A, et al. Potential therapeutic effects of natural heme oxygenase-1 inducers in cardiovascular diseases. Antioxid Redox Signal 2013; 18: 507-21.
87. [87] Allegra A, Penna G, Alonci A, et al. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol 2013; 90: 441-68.
88. [88] DeNicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106-9.
89. [89] Lister A, Nedjadi T, Kitteringham NR, et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 2011; 10: 37-42.
90. [90] Alfadda AA, Sallam RM. Reactive oxygen species in health and disease. J Biomed Biotechnol 2012; 2012: 936486.
91. [91] Ma Q. Role of nrf2 in oxidative stress and toxicity. Ann Rev Pharmacol Toxicol 2013; 53: 401-26.
92. [92] Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008; 68: 1303-9.
93. [93] Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLOS Med 2006; 3: e420-e425.
94. [94] Copple IM. The keap1-nrf2 cell defense pathway-a promising therapeutic target? Adv Pharmacol 2012; 63: 43-8.
95. [95] Kincaid B, Bossy-Wetzel E. Forever young: SIRT3 a shield against mitochondrial meltdown, aging, and neurodegeneration. Front Aging Neurosci 2013; 5: 48-53.
96. [96] Donmez G, Outeiro TF. SIRT1 and SIRT2: Emerging targets in neurodegeneration. EMBO Molecular Medicine 2013; 5: 344-52.
97. [97] de Oliveira RM, Pais TF, Outeiro TF. Irtuins: Common targets in aging and in neurodegeneration. Current Drug Targets 2010; 11: 1270-80.
98. [98] Radak Z, Koltai E, Taylor AW, et al. Redox-regulating sirtuins in aging, caloric restriction, and exercise. Free Radic Biol Med 2013; 58: 87-97.
99. [99] Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 2012; 11: 443-461.
100. [100] Kazantsev AG, Outeiro TF. Editorial on special topic: Sirtuins in metabolism, aging, and disease. Frontiers Pharmacol 2012; 3 APR.
101. [101] Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 2010; 12: 662-7.
102. [102] Someya S, Yu W, Hallows WC, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010; 143: 802-12.
103. [103] Jacobs KM, Pennington JD, Bisht KS, et al. SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression. Int J Biol Sci 2008; 4: 291-9.
104. [104] Farghali H, Kutinova Canova N, Lekic N. Resveratrol and related compounds as antioxidants with an allosteric mechanism of action in epigenetic drug targets. Physiol Res 2013; 62: 1-13.
105. [105] Villalba JM, Alcain FJ. Sirtuin activators and inhibitors. Biofactors 2012; 38: 349-59.
106. [106] Lotito SB, Frei B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med 2006; 41: 1727-46.
107. [107] Wahlqvist ML. Antioxidant relevance to human health. Asia Pac J Clin Nutr 2013; 22: 171-6.
108. [108] Doehner W, Landmesser U, editors. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol; 2011: Elsevier.
109. [109] Long LH, Hoi A, Halliwell B. Instability of, and generation of hydrogen peroxide by, phenolic compounds in cell culture media. Arch Biochem Biophys 2010; 501: 162-9.
110. [110] Kondakci E, Ozyurek M, Guclu K, Apak R. Novel pro-oxidant activity assay for polyphenols, vitamins C and E using a modified CUPRAC method. Talanta 2013; 115: 583-9.
111. [111] Forester SC, Lambert JD. The role of antioxidant versus prooxidant effects of green tea polyphenols in cancer prevention. Mol Nutr Food Res 2011; 55: 844-54.
112. [112] Farina N, Isaac M, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev 2012; 11: CD002854.
113. [113] Myung SK, Ju W, Cho B, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 346: f10.
114. [114] Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012; 3: CD007176.
115. [115] Dolara P, Bigagli E, Collins A. Antioxidant vitamins and mineral supplementation, life span expansion and cancer incidence: a critical commentary. Eur J Nutr 2012; 51: 769-81.
116. [116] Rice-Evans C. Flavonoid antioxidants. Curr Med Chem 2001; 8: 797-807.
117. [117] Firuzi O, Mladenka P, Petrucci R, Marrosu G, Saso L. Hypochlorite scavenging activity of flavonoids. J Pharm Pharmacol 2004; 56: 801-7.
118. [118] Firuzi O, Lacanna A, Petrucci R, Marrosu G, Saso L. Evaluation of the antioxidant activity of flavonoids by “ferric reducing antioxidant power” assay and cyclic voltammetry. Biochim Biophys Acta 2005; 1721: 174-84.
119. [119] de la Lastra CA, Villegas I. Resveratrol as an antioxidant and prooxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007; 35: 1156-60.
120. [120] Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease: Springer; 2007. p. 105-25.
121. [121] Jena S, Chainy GB. Regulation of expression of antioxidant enzymes by vitamin E and curcumin in L-thyroxine-induced oxidative stress in rat renal cortex. Mol Biol Rep 2011; 38: 1047-54.
122. [122] Sahoo DK, Roy A, Chainy GB. Protective effects of vitamin E and curcumin on L-thyroxine-induced rat testicular oxidative stress. Chem Biol Interact 2008; 176: 121-8.
123. [123] Pedersen JZ, Oliveira C, Incerpi S, et al. Antioxidant activity of 4methylcoumarins. J Pharm Pharmacol 2007; 59: 1721-8.
124. [124] Morabito G, Trombetta D, Singh Brajendra K, et al. Antioxidant properties of 4-methylcoumarins in in vitro cell-free systems. Biochimie 2010; 92: 1101-7.
125. [125] Natella F, Lorrain B, Prasad AK, et al. 4-Methylcoumarins as antioxidants: Scavenging of peroxyl radicals and inhibition of human low-density lipoprotein oxidation. Biochimie 2010; 92: 1147-52.
126. [126] Petrucci R, Saso L, Kumar V, et al. A spectroelectrochemical and chemical study on oxidation of 7, 8-dihydroxy-4-methylcoumarin (DHMC) and some related compounds in aprotic medium. Biochimie 2010; 92: 1123-9.
127. [127] Kostova I, Bhatia S, Grigorov P, et al. Coumarins as antioxidants. Curr Med Chem 2011; 18: 3929-51.
128. [128] Garrido J, Gaspar A, Garrido EM, et al. Alkyl esters of hydroxycinnamic acids with improved antioxidant activity and lipophilicity protect PC12 cells against oxidative stress. Biochimie 2012; 94: 961-7.
129. [129] Razzaghi-Asl N, Garrido J, Khazraei H, Borges F, Firuzi O. Antioxidant Properties of Hydroxycinnamic Acids: A Review of Structure-Activity Relationships. Curr Med Chem 2013; 20: 4436-50.
130. [130] Gaspar A, Martins M, Silva P, et al. Dietary phenolic acids and derivatives. Evaluation of the antioxidant activity of sinapic acid and its alkyl esters. J Agric Food Chem 2010; 58: 11273-11280.
131. [131] Mladnka P, Macáková K, Filipsk T, et al. In vitro analysis of iron chelating activity of flavonoids. J Inorg Biochem 2011; 105: 693-701.
132. [132] Mladnka P, Macáková K, Zatloukalová L, et al. In vitro interactions of coumarins with iron. Biochimie 2010; 92: 1108-14.
133. [133] Scapagnini G, Sonya V, Nader AG, et al. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 2011; 44: 192-201.
134. [134] Kesherwani V, Atif F, Yousuf S, Agrawal SK. Resveratrol protects spinal cord dorsal column from hypoxic injury by activating Nrf-2. Neuroscience 2013; 241: 80-8.
135. [135] Neves AR, Lucio M, Lima JL, Reis S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr Med Chem 2012; 19: 1663-81.
136. [136] Fan X, Zhang C, Liu D-b, Yan J, Liang H-p. The clinical applications of curcumin: current state and the future. Curr Pharm Design 2013; 19: 2011-31.
137. [137] Correa F, Buelna-Chontal M, et al. Curcumin maintains cardiac and mitochondrial function in chronic kidney disease. Free Radic Biol Med 2013; 61C: 119-29.
138. [138] Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its antiinflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol 2012; 26: 1512-24.
139. [139] Carbone C, Pignatello R, Musumeci T, Puglisi G. Chemical and technological delivery systems for idebenone: a review of literature production. Expert Opin Drug Del 2012; 9: 1377-92.
140. [140] Senin U, Parnetti L, Barbagallo-Sangiorgi G, et al. Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 1992; 15: 249-60.
141. [141] Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol 1994; 9: 161-7.
142. [142] Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta 2012; 1822: 631-8.
143. [143] Reiter RJ, Tan D-X. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 2003; 58: 10-9.
144. [144] Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem 2013; 13: 373-84.
145. [145] Gitto E, Aversa S, Reiter RJ, Barberi I, Pellegrino S. Update on the use of melatonin in pediatrics. J Pin Res 2011; 50: 21-8.
146. [146] Miller S, Wallace E, Walker D. Antioxidant therapies: a potential role in perinatal medicine. Neuroendocrinology 2012; 96: 13-23.
147. [147] Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal cord injury. Biochim Biophys Acta 2012; 1822: 675-684.
148. [148] Reiter R, Tan D, Korkmaz A, Fuentes-Broto L. Drug-mediated ototoxicity and tinnitus: alleviation with melatonin. J Physiol Pharmacol 2011; 62: 151-6.
149. [149] Schacht J, Talaska AE, Rybak LP. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec 2012; 295: 1837-50.
150. [150] Mazer M, Perrone J. Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management. J Med Toxicol 2008; 4: 2-6.
151. [151] Hillas G, Nikolakopoulou S, Hussain S, Vassilakopoulos T. Antioxidants and Mucolytics in COPD Management: When (if ever) and in Whom? Curr Drug Targets 2013; 14: 225-34.
152. [152] Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 2013; 1830: 4117-29.
153. [153] Arakawa M. N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology. Cerebellum 2007; 6: 308-14.
154. [154] Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. JPN 2011; 36: 78-84.
155. [155] Berk M, Malhi GS, Gray LJ, Dean OM. The promise of Nacetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013; 34: 167-77.
156. [156] Bridgeman M, Marsden M, Selby C, Morrison D, MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49: 670-5.
157. [157] Rahman I, MacNee W. Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 2012; 12: 256-65.
158. [158] Feldman L, Sherman RA, Weissgarten J, editors. NAcetylcysteine Use for Amelioration of AminoglycosideInduced Ototoxicity in Dialysis Patients. Semin Dialysis; 2012: Wiley Online Library.
159. [159] Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 2012; 30: 2408-17.
160. [160] Cazzola M, Floriani I, Page C. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm Pharmacol Ther 2010; 23: 135-44.
161. [161] Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004; 30: 143-52.
162. [162] Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin Drug Metab Toxicol 2009; 5: 11.
163. [163] Osoata GO, Hanazawa T, Brindicci C, et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest 2009; 135: 1513-20.
164. [164] Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 2012; 1822: 625-30.
165. [165] Drake J, Kanski J, Varadarajan S, Tsoras M, Butterfield DA. Elevation of brain glutathione by glutamylcysteine ethyl ester protects against peroxynitrite induced oxidative stress. J Neurosci Res 2002; 68: 776-84.
166. [166] Drake J, Sultana R, Aksenova M, Calabrese V, Butterfield DA. Elevation of mitochondrial glutathione by glutamylcysteine ethyl ester protects mitochondria against peroxynitrite induced oxidative stress. J Neurosci Res 2003; 74: 917-27.
167. [167] Rochette L, Ghibu S, Richard C, et al. Direct and indirect antioxidant properties of alpha-lipoic acid and therapeutic potential. Mol Nutr Food Res 2013; 57: 114-25.
168. [168] Ogborne RM, Rushworth SA, O’Connell MA. -lipoic acid-induced heme oxygenase-1 expression is mediated by nuclear factor erythroid 2-related factor 2 and p38 mitogen-activated protein kinase in human monocytic cells. Arterioscler Thromb Vasc Biol 2005; 25: 2100-05.
169. [169] Heitzer T, Finckh B, Albers S, et al. Beneficial effects of -lipoic acid and ascorbic acid on endothelium-dependent, nitric oxidemediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001; 31: 53-61.
170. [170] Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study. Circulation 2005; 111: 343-8.
171. [171] Guerrero-Beltrán CE, Calderón-Oliver M, Pedraza-Chaverri J, Chirino YI. Protective effect of sulforaphane against oxidative stress: recent advances. Exp Toxicol Pathol 2012; 64: 503-8.
172. [172] Kensler TW, Egner PA, Agyeman AS, et al. Keap1-Nrf2 signaling: a target for cancer prevention by sulforaphane. Nat Prod Cancer Preven Ther: Springer; 2013. p. 163-77.
173. [173] Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother 2010; 11: 1753-63.
174. [174] Watanabe T, Tahara M, Todo S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther 2008; 26: 101-14.
175. [175] Noor JI, Ikeda T, Mishima K, et al. Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy. Stroke 2005; 36: 2468-74.
176. [176] Villamena FA, Das A, Nash KM. Potential implication of the chemical properties and bioactivity of nitrone spin traps for therapeutics. Fut Med Chem 2012; 4: 1171-207.
177. [177] Floyd RA, Kopke RD, Choi C-H, et al. Nitrones as therapeutics. Free Radic Biol Med 2008; 45: 1361-74.
178. [178] Diener H-C, Lees KR, Lyden P, et al. NXY-059 for the Treatment of Acute Stroke Pooled Analysis of the SAINT I and II Trials. Stroke 2008; 39: 1751-8.
179. [179] Floyd RA, Castro Faria Neto HC, Zimmerman GA, Hensley K, Towner RA. Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines. Free Radic Biol Med 2013; 62: 145-56.
180. [180] Sena E, Wheble P, Sandercock P, Macleod M. Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke 2007; 38: 388-94.
181. [181] Flessas II, Papalois AE, Toutouzas K, Zagouri F, Zografos GC. Effects of lazaroids on intestinal ischemia and reperfusion injury in experimental models. J Surg Res 2011; 166: 265-74.
182. [182] Hall ED, Vaishnav RA, Mustafa AG. Antioxidant Therapies for Traumatic Brain Injury. Neurotherapeutics 2010; 7: 51-61.
183. [183] Gibson SB, Bromberg MB, editors. Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside. Semin Neurol; 2012: Thieme Medical Publishers.
184. [184] Buettner GR. Superoxide dismutase in redox biology: the roles of superoxide and hydrogen peroxide. Anticancer Agents Med Chem 2011; 11: 341.
185. [185] Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Rad Res 1999; 31: 261-72.
186. [186] Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 2002; 54: 587-606.
187. [187] Batini-Haberle I, Rebouças JS, Spasojevi I. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal 2010; 13: 877-918.
188. [188] Aston K, Rath N, Naik A, et al. Computer-aided design (CAD) of Mn(II) complexes: superoxide dismutase mimetics with catalytic activity exceeding the native enzyme. Inorg Chem 2001; 40: 1779-89.
189. [189] Camara AK, Lesnefsky EJ, Stowe DF. Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal 2010; 13: 279-347.
190. [190] Comhair SA, Erzurum SC. Redox control of asthma: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2010; 12: 93-124.
191. [191] de Haan J, Cooper M. Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunction. Front Biosci 2011; 3: 709.
192. [192] Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58: 87-114.
193. [193] Afanas' ev I. ROS and RNS signaling in heart disorders: could antioxidant treatment be successful? Oxid Med Cell Longev 2011; 2011.
194. [194] Bulkley G. Free radical-mediated reperfusion injury: a selective review. Br J Cancer 1987; 8: 66.
195. [195] Saugstad OD. Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Pediatrics 1996; 98: 103-7.
196. [196] Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T. Mammalian xanthine oxidoreductase-mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J 2008; 275: 3278-89.
197. [197] Boda D, Nemeth I, Hencz P, Denes K. Effect of allopurinol treatment in premature infants with idiopathic respiratory distress syndrome. Dev Pharmacol Ther 1984; 7: 357-63.
198. [198] Van Bel F, Shadid M, Moison RM, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics 1998; 101: 185-93.
199. [199] Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I. Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns. Pediatr Neurol 2007; 36: 17-24.
200. [200] Kahles T, Brandes RP. NADPH oxidases as therapeutic targets in ischemic stroke. Cell Mol Life Sci 2012; 69: 2345-63.
201. [201] Coso S, Harrison I, Harrison CB, et al. NADPH oxidases as regulators of tumor angiogenesis: current and emerging concepts. Antioxid Redox Signal 2012; 16: 1229-47.
202. [202] Frey RS, Ushio-Fukai M, Malik AB. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 2009; 11: 791-810.
203. [203] Sorce S, Krause K-H, Jaquet V. Targeting NOX enzymes in the central nervous system: therapeutic opportunities. Cell Mol Life Sci 2012; 69: 2387-407.
204. [204] Radermacher KA, Wingler K, Langhauser F, et al. Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. Antioxid Redox Signal 2013; 18: 1418-27.
205. [205] Octavia Y, Brunner-La Rocca HP, Moens AL. NADPH oxidasedependent oxidative stress in the failing heart: From pathogenic roles to therapeutic approach. Free Radic Biol Med 2012; 52: 291-7.
206. [206] Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vasc Pharmacol 2012; 56: 216-31.
207. [207] Heumüller S, Wind S, Barbosa-Sicard E, et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008; 51: 211-7.
208. [208] Sedeek M, Montezano AC, Hebert RL, et al. Oxidative stress, Nox isoforms and complications of diabetes—potential targets for novel therapies. J Cardiovasc Pharmacol Transl Res 2012; 5: 509-18.
209. [209] Wind S, Beuerlein K, Eucker T, et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 2010; 161: 885-98.
210. [210] Shimazu T, Inoue I, Araki N, et al. A peroxisome proliferatoractivated receptor- agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005; 36: 353-9.
211. [211] Da Ros R, Assaloni R, Ceriello A. The preventive antioxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabetic Med 2004; 21: 1249-52.
212. [212] Golbidi S, Laher I. Antioxidant therapy in human endocrine disorders. Med Sci Monit 2010; 16: RA9.
213. [213] Lu X, Murphy TC, Nanes MS, Hart CM. PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B. Am J Physiol Lung Cell Mol Physiol 2010; 299: L559-66.
214. [214] Nakamura T, Yamamoto E, Kataoka K, et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008; 51: 296-301.
215. [215] Morita T. Celastrol: a new therapeutic potential of traditional Chinese medicine. Am J Hypertens 2010; 23: 821-7.
216. [216] Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci 2005; 50: 1807-12.
217. [217] Tapsell LC, Hemphill I, Cobiac L, et al. Health benefits of herbs and spices: the past, the present, the future. Medic J Austr 2006; 185: S4-24.
218. [218] Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidantrelated diseases. Inflam Allergy Drug Targets 2009; 8: 2-10.
219. [219] Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol 2011; 21: 841-60.
220. [220] Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007; 6: 110-19.
221. [221] Polyak SJ, Morishima C, Lohmann V, et al. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA 2010; 107: 5995-9.
222. [222] Freedman ND, Curto TM, Morishima C, et al. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther 2011; 33: 127-37.
223. [223] Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-7.
224. [224] Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008; 15: 9-20.
225. [225] Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med 2002; 113: 506-15.
226. [226] Lu S, Guo X, Zhao P. Effect of ginkgo biloba extract 50 on immunity and antioxidant enzyme activities in ischemia reperfusion rats. Molecules 2011; 16: 9194-206.
227. [227] Boghdady NAE. Antioxidant and antiapoptotic effects of proanthocyanidin and ginkgo biloba extract against doxorubicininduced cardiac injury in rats. Cell Biochemistry and Function 2013; 31: 344-51.
228. [228] Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 2003; 60: 1779-92.
229. [229] Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 2002; 67: 235-57.
230. [230] Brondino N, De Silvestri A, Re S, et al. A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders: From ancient tradition to modern-day medicine. Evid Based Complement Alternat Med 2013; 2013.
231. [231] Zhang WF, Tan YL, Zhang XY, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: A randomized, double-blind, placebo-controlled trial. J Clin Psychol 2011; 72: 615-621.
232. [232] Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, efficacy, safety, and uses. J Food Sci 2008; 73: R14-19.
233. [233] Bolkent S, Yanardag R, Karabulut-Bulan O, Yesilyaprak B. Protective role of Melissa officinalis L. extract on liver of hyperlipidemic rats: a morphological and biochemical study. J Ethnopharmacol 2005; 99: 391-8.
234. [234] de Sousa AC, Alviano DS, Blank AF, et al. Melissa officinalis L. essential oil: antitumoral and antioxidant activities. J Pharm Pharmacol 2004; 56: 677-81.
235. [235] Meftahizade H, Sargsyan E, Moradkhani H. Investigation of antioxidant capacity of Melissa officinalis L. essential oils. J Med Plant Res 2013; 4: 1391-5.
236. [236] Akhondzadeh S, Noroozian M, Mohammadi M, et al. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiat 2003; 74: 863-6.
237. [237] Kennedy DO, Little W, Scholey AB. Attenuation of laboratoryinduced stress in humans after acute administration of Melissa officinalis (lemon balm). Psychosom Med 2004; 66: 607-13.
238. [238] Burns A, Perry E, Holmes C, et al. A double-blind placebocontrolled randomized trial of melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. Dement Geriatr Cog Disord 2011; 31: 158-64.
239. [239] Fazli D, Malekirad AA, Pilevarian AA, et al. Effects of melissa officinalis l. on oxidative status and biochemical parameters in occupationally exposed workers to aluminum: A before after clinical trial. Int J Pharmacol 2012; 8: 455-8.
240. [240] Zeraatpishe A, Oryan S, Bagheri MH, et al. Effects of Melissa officinalis L. on oxidative status and DNA damage in subjects exposed to long-term low-dose ionizing radiation. Toxicol Indust Health 2011; 27: 205-212.
241. [241] Ulbricht C, Brendler T, Gruenwald J, et al. Lemon balm (Melissa officinalis L.): an evidence-based systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother 2005; 5: 71-114.
242. [242] Lopez-Pedrera C, Ruiz-Limon P, Valverde-Estepa A, Barbarroja N, Rodriguez-Ariza A. To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer. Curr Drug Targets 2012; 13: 829-41.
243. [243] Marzilli M. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs 2010; 10 Suppl 1: 3-9.
244. [244] Knorr M, Hausding M, Kroller-Schuhmacher S, et al. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol 2011; 31: 2223-31.
245. [245] Rosenkranz AC, Lob H, Breitenbach T, Berkels R, Roesen R. Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur J Pharmacol 2006; 529: 55-62.
246. [246] Weseler AR, Bast A. Oxidative stress and vascular function: implications for pharmacologic treatments. Curr Hypertens Rep 2010; 12: 154-61.
247. [247] Oak J-H, Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007; 56: 118-26.
248. [248] Gabriely I, Yang XM, Cases JA, et al. Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol Regul Integr Comp Physiol 2001; 281: R795-802.
249. [249] Münzel T, Keaney JF. Are ACE inhibitors a “magic bullet” against oxidative stress? Circulation 2001; 104: 1571-74.
250. [250] Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
251. [251] Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endotheliumdependent coronary vasomotion. New Eng J Med 1995; 332: 488-93.
252. [252] Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dosedependent regulation of NAD (P) H oxidase expression by angiotensin II in human endothelial cells protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: 1845-51.
253. [253] Heeba G, Hassan MK, Khalifa M, Malinski T. Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins. J Cardiovasc Pharmacol 2007; 50: 391-8.
254. [254] Antoniades C, Demosthenous M, Reilly S, et al. Myocardial Redox State Predicts In-Hospital Clinical Outcome After Cardiac SurgeryEffects of Short-Term Pre-Operative Statin Treatment. J Am Coll Med 2012; 59: 60-70.
255. [255] Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007; 25: 731-41.
256. [256] Khan MU, Zhao W, Zhao T, et al. Nebivolol, a multifaceted antioxidant and cardioprotectant in hypertensive heart disease. J Cardiovasc Pharmacol 2013; 62: 445-51.
257. [257] Godfraind T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci 2005; 360: 2259-72.
258. [258] Tousoulis D, Papageorgiou N, Briasoulis A, et al. Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies. Heart Fail Rev 2012; 17: 65-79.
259. [259] Daosukho C, Ittarat W, Lin S-m, et al. Induction of manganese superoxide dismutase (MnSOD) mediates cardioprotective effect of tamoxifen (TAM). J Mol Cell Cardiol 2005; 39: 792-803.
260. [260] Wakade C, Khan MM, De Sevilla LM, et al. Tamoxifen neuroprotection in cerebral ischemia involves attenuation of kinase activation and superoxide production and potentiation of mitochondrial superoxide dismutase. Endocrinology 2008; 149: 367-79.
261. [261] Shinohara Y, Inoue S. Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction. J Stroke Cerebrovasc Dis 2013; 22: 668-74.
262. [262] Comhaire F, Decleer W. Quantifying the effectiveness and costefficiency of food supplementation with antioxidants for male infertility. Reprod Biomed Online 2011; 23: 361-2.
263. [263] Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology 2012; 56: 2172-9.
264. [264] Senarathna SM, Sri Ranganathan S, Buckley N, Fernandopulle R. A cost effectiveness analysis of the preferred antidotes for acute paracetamol poisoning patients in Sri Lanka. BMC Clin Pharmacol 2012; 12: 6.
265. [265] Cicero AF, Borghi C. Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals. Curr Hypertens Rep 2013; 15: 260-7.
266. [266] Ankola DD, Viswanad B, Bhardwaj V, Ramarao P, Kumar MN. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Eur J Pharm Biopharm 2007; 67: 361-9.
267. [267] Cooper K, Squires H, Carroll C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-206.
268. [268] Milic N, Milosevic N, Suvajdzic L, Zarkov M, Abenavoli L. New therapeutic potentials of milk thistle (Silybum marianum). Nat Prod Commun 2013; 8: 1801-10.
269. [269] Nicolson GL. Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function. Pathol Oncol Res 2005; 11: 139-44.
270. [270] Li XX, Han M, Wang YY, Liu JP. Chinese herbal medicine for gout: a systematic review of randomized clinical trials. Clin Rheumatol 2013; 32: 943-59.
271. [271] Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2008: Cd007176.
272. [272] Miller ER, III, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
273. [273] Gerss J, Kopcke W. The questionable association of vitamin E supplementation and mortality--inconsistent results of different meta-analytic approaches. Cell Mol Biol (Noisy-le-grand) 2009; 55 Suppl: 1111-1120.
274. [274] Shekelle PG, Morton SC, Jungvig LK, et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med 2004; 19: 380-9.
275. [275] Violi F, Cangemi R. Statin treatment as a confounding factor in human trials with vitamin E. J Nutr 2008; 138: 1179-81.
276. [276] Goralczyk R. Beta-carotene and lung cancer in smokers: review of hypotheses and status of research. Nutr Cancer 2009; 61: 767-74.
277. [277] Krinsky NI, Johnson EJ. Carotenoid actions and their relation to health and disease. Mol Aspects Med 2005; 26: 459-516.
278. [278] Xu DX, Chen YH, Wang H, et al. Effect of N-acetylcysteine on lipopolysaccharide-induced intra-uterine fetal death and intrauterine growth retardation in mice. Toxicol Sci 2005; 88: 525-33.
279. [279] Zhao M, Chen YH, Chen X, et al. Folic acid supplementation during pregnancy protects against lipopolysaccharide-induced neural tube defects in mice. Toxicol Lett 2014; 224: 201-8.
280. [280] Pizzurro DM, Dao K, Costa LG. Astrocytes protect against diazinon-and diazoxon-induced inhibition of neurite outgrowth by regulating neuronal glutathione. Toxicology 2014; 319: 59-68.
281. [281] Mazhar FM, Moawad KM, El-Dakdoky MH, Amer AS. Fetotoxicity of 2,4-dichlorophenoxyacetic acid in rats and the protective role of vitamin e. Toxicol Indust Health 2014; 30: 480-8.
282. [282] Abd El-Aziz GS, El-Fark MMO, Saleh HAM. The Prenatal Toxic Effect of Methylmercury on the Development of the Appendicular Skeleton of Rat Fetuses and the Protective Role of Vitamin E. Anat Rec 2012; 295: 939-49.
283. [283] Cordova FM, Aguiar AS, Peres TV, et al. Manganese-exposed developing rats display motor deficits and striatal oxidative stress that are reversed by Trolox. Arch Toxicol 2013; 87: 1231-44.
284. [284] Jahnke G, Marr M, Myers C, et al. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 1999; 50: 271-9.
285. [285] Lu B, Wu X, Shi J, Dong Y, Zhang Y. Toxicology and safety of antioxidant of bamboo leaves. Part 2: Developmental toxicity test in rats with antioxidant of bamboo leaves. Food Chem Toxicol 2006; 44: 1739-43.
286. [286] Sun AY, Wang Q, Simonyi A, Sun GY. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 2010; 41: 375-83.
287. [287] Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: Role of resveratrol in microglial activation. Eur J Pharmacol 2010; 636: 1-7.
288. [288] Hamaguchi T, Ono K, Yamada M. Curcumin and Alzheimer's disease. CNS Neurosci Ther 2010; 16: 285-97.
289. [289] Pace A, Giannarelli D, Galiè E, et al. Vitamin e neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial. Neurology 2010; 74: 762-6.
290. [290] Bosnjak ZJ, Yan Y, Canfield S, et al. Ketamine induces toxicity in human neurons differentiated from embryonic stem cells via mitochondrial apoptosis pathway. Curr Drug Safety 2012; 7: 106-19.
291. [291] Sies H, Hollman PC, Grune T, et al. Protection by flavanol-rich foods against vascular dysfunction and oxidative damage: 27th Hohenheim Consensus Conference. Adv Nutr 2012; 3: 217-21.
292. [292] Leonarduzzi G, Sottero B, Poli G. Targeting tissue oxidative damage by means of cell signaling modulators: the antioxidant concept revisited. Pharmacol Ther 2010; 128: 336-74.
293. [293] Leonarduzzi G, Testa G, Sottero B, Gamba P, Poli G. Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem 2010; 17: 74-95.
294. [294] Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res 2011; 4: 1158-71.
295. [295] Belkacemi A, Doggui S, Dao L, Ramassamy C. Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med 2011; 13: e34.
296. [296] Amri A, Chaumeil J, Sfar S, Charrueau C. Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 2012; 158: 182-93.
297. [297] Beckman JS, Minor R, White C, et al. Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance. J Biol Chem 1988; 263: 6884-92.
298. [298] Rosenbaugh EG, Savalia KK, Manickam DS, Zimmerman MC. Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol 2013; 304: R917-28.
299. [299] Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J 2009; 23: 1384-95.
300. [300] Lee D, Erigala VR, Dasari M, et al. Detection of hydrogen peroxide with chemiluminescent micelles. Int J Nanomed 2008; 3: 471-6.
301. [301] Kim S, Park H, Song Y, et al. Reduction of oxidative stress by phydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant. Biomaterials 2011; 32: 3021-9.
302. [302] Rosenbaugh EG, Roat JW, Gao L, et al. The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase. Biomaterials 2010; 31: 5218-26.
303. [303] Muro S, Dziubla T, Qiu W, et al. Endothelial targeting of highaffinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther 2006; 317: 1161-9.
304. [304] Bousova I, Skalova L. Inhibition and induction of glutathione Stransferases by flavonoids: possible pharmacological and toxicological consequences. Drug Metab Rev 2012; 44: 267-86.
305. [305] Bousova I, Hajek J, Drsata J, Skalova L. Naturally occurring flavonoids as inhibitors of purified cytosolic glutathione Stransferase. Xenobiotica 2012; 42: 872-9.
306. [306] Bartikova H, Skalova L, Drsata J, Bousova I. Interaction of Anthocyanins with Drug-metabolizing and Antioxidant Enzymes. Curr Med Chem 2013; 20: 4665-79.
307. [307] Benfeito S, Oliveira C, Soares P, et al. Antioxidant therapy: still in search of the 'magic bullet'. Mitochondrion 2013; 13: 427-35.
308. [308] Murphy MP. Antioxidants as therapies: can we improve on nature? Free Radic Biol Med 2013; 8: 20-3.
309. [309] Gori T, Münzel T. Oxidative stress and endothelial dysfunction: Therapeutic implications. Ann Med 2011; 43: 259-72.
310. [310] Smith RA, Hartley RC, Cochemé HM, Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci 2012; 33: 341-52.
311. [311] Stopeck AT, Brown-Glaberman U, Wong HY, et al. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis 2012; 29: 807-19.
312. [312] Mayne ST. Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research. J Nutr 2003; 133: 933-40.
313. [313] Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2009; 27: 120-39.
314. [314] Teixeira J, Silva T, Andrade PB, Borges F. Alzheimer's disease and antioxidant therapy: how long how far? Curr Med Chem 2013; 20: 2939-52.
315. [315] Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007; 47: 629-56.
316. [316] Kahles T, Brandes RP. Which NADPH oxidase isoform is relevant for ischemic stroke? The case for nox 2. Antioxid Redox Signal 2013; 18: 1400-17.
317. [317] Dodson M, Darley-Usmar V, Zhang J. Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic Biol Med 2013; 63: 207-21.
318. [318] Tahara EB, Navarete FD, Kowaltowski AJ. Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation. Free Radic Biol Med 2009; 46: 1283-97.
319. [319] Murphy MP. Mitochondria--a neglected drug target. Curr Opin Investig Drugs 2009; 10: 1022.
320. [320] Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu Rev Pathol 2010; 5: 297-303.
321. [321] Hernandez-Resendiz S, Buelna-Chontal M, Correa F, Zazueta C. Targeting mitochondria for cardiac protection. Curr Drug Targets 2013; 14: 586-600.
322. [322] Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007; 47: 629-56.
323. [323] Smith R, Murphy MP. Mitochondria-targeted antioxidants as therapies. Discov Med 2011; 11: 106-14.
324. [324] Prime TA, Blaikie FH, Evans C, et al. A mitochondria-targeted Snitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury. Proc Natl Acad Sci USA 2009; 106: 10764-9.
325. [325] Teixeira J, Soares P, Benfeito S, et al. Rational discovery and development of a mitochondria-targeted antioxidant based on cinnamic acid scaffold. Free Radic Res 2012; 46: 600-11.
326. [326] Szeto HH. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J 2006; 8: E521-31.
327. [327] Reddy PH, Tripathi R, Troung Q, et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 2012; 1822: 639-49.
328. [328] Su B, Wang X, Bonda D, et al. Abnormal mitochondrial dynamics—a novel therapeutic target for Alzheimer's disease? Mol Neurobiol 2010; 41: 87-96.
329. [329] Moreira PI, Zhu X, Wang X, et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 2010; 1802: 212-20.
330. [330] Severina II, Severin FF, Korshunova GA, et al. In search of novel highly active mitochondria-targeted antioxidants: thymoquinone and its cationic derivatives. FEBS lett 2013; 587: 2018-24.
331. [331] Dulak J, Zagorska A, Wegiel B, Loboda A, Jozkowicz A. New strategies for cardiovascular gene therapy. Cell Biochem Biophys 2006; 44: 31-42.
332. [332] Levonen A-L, Vähäkangas E, Koponen JK, Ylä-Herttuala S. Antioxidant Gene Therapy for Cardiovascular Disease Current Status and Future Perspectives. Circulation 2008; 117: 2142-50.
333. [333] Navarro-Yepes J, Zavala-Flores L, Annadurai A, et al. Antioxidant gene therapy against neuronal cell death. Pharmacol Ther 2014; 142(2): 206-30.
334. [334] Liu Y, Tang L, Chen B. Effects of antioxidant gene therapy on retinal neurons and oxidative stress in a model of retinal ischemia/reperfusion. Free Radic Biol Med 2012; 52: 909-15.
335. [335] Li Q, Bolli R, Qiu Y, et al. Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. Circulation 1998; 98: 1438-48.
336. [336] Li Q, Bolli R, Qiu Y, et al. Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation 2001; 103: 1893-8.
337. [337] Koepke JI, Nakrieko KA, Wood CS, et al. Restoration of peroxisomal catalase import in a model of human cellular aging. Traffic 2007; 8: 1590-600.
338. [338] Undyala V, Terlecky SR, Vander Heide RS. Targeted intracellular catalase delivery protects neonatal rat myocytes from hypoxiareoxygenation and ischemia-reperfusion injury. Cardiovasc Pathol 2011; 20: 272-80.
339. [339] Li D, Lai Y, Yue Y, et al. Ectopic catalase expression in mitochondria by adeno-associated virus enhances exercise performance in mice. PLoS ONE 2009; 4.
340. [340] Sorokina EM, Feinstein SI, Milovanova TN, Fisher AB. Identification of the amino acid sequence that targets peroxiredoxin 6 to lysosome-like structures of lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009; 297: L871-80.
341. [341] Dae WK, So YK, Sun HL, et al. Protein transduction of an antioxidant enzyme: Subcellular localization of superoxide dismutase fusion protein in cells. J Biocem Mol Biol 2008; 41: 170-5.
342. [342] Chen K, Kirber MT, Xiao H, Yang Y, Keaney Jr JF. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol 2008; 181: 1129-39.
343. [343] Laguerre M, Bayrasy C, Lecomte J, et al. How to boost antioxidants by lipophilization? Biochimie 2013; 95: 20-6.
344. [344] Bayrasy C, Chabi B, Laguerre M, et al. Boosting antioxidants by lipophilization: A strategy to increase cell uptake and target mitochondria. Pharmaceut Res 2013; 30: 1979-89.
345. [345] Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010; 19: 330-38.
346. [346] Reiter RJ, Tan D-x, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 2000; 7: 444-58.
347. [347] Alkaitis MS, Crabtree MJ. Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling. Curr Heart Fail Rep 2012; 9: 200-10.
348. [348] Solevag AL, Nakstad B. Neuroprotective treatment for perinatal asphyxia. Tidsskr Nor Laegeforen 2012; 132: 2396-9.
349. [349] Lee BE, Toledo AH, Anaya-Prado R, Roach RR, Toledo-Pereyra LH. Allopurinol, xanthine oxidase, and cardiac ischemia. J Invest Med 2009; 57: 902-9.
350. [350] Peglow S, Toledo AH, Anaya-Prado R, Lopez-Neblina F, Toledo-Pereyra LH. Allopurinol and xanthine oxidase inhibition in liver ischemia reperfusion. J Hepatobiliary Pancreat Sci 2011; 18: 137-46.
351. [351] Blackhall ML, Coombes JS, Fassett R. The relationship between antioxidant supplements and oxidative stress in renal transplant recipients: A review. Asaio Journal 2004; 50: 451-7.